4D Molecular Therapeutics (NASDAQ:FDMT) Sees Large Volume Increase – Here’s What Happened

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) saw strong trading volume on Friday . 2,782,783 shares traded hands during trading, an increase of 269% from the previous session’s volume of 753,612 shares.The stock last traded at $9.7830 and had previously closed at $8.97.

Analyst Ratings Changes

Several brokerages recently commented on FDMT. HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. Jefferies Financial Group reissued a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, The Goldman Sachs Group set a $33.00 target price on 4D Molecular Therapeutics in a report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.88.

4D Molecular Therapeutics Price Performance

The stock has a market cap of $512.34 million, a P/E ratio of -3.79 and a beta of 2.77. The company has a fifty day moving average of $9.48 and a 200 day moving average of $9.29.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The firm had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. As a group, analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.74 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. grew its position in 4D Molecular Therapeutics by 23.9% in the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock worth $42,399,000 after buying an additional 1,090,000 shares during the last quarter. Janus Henderson Group PLC grew its position in 4D Molecular Therapeutics by 13.2% in the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after buying an additional 611,276 shares during the last quarter. Goldman Sachs Group Inc. grew its position in 4D Molecular Therapeutics by 4.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock worth $32,272,000 after buying an additional 174,489 shares during the last quarter. State Street Corp grew its position in 4D Molecular Therapeutics by 197.5% in the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after buying an additional 1,785,106 shares during the last quarter. Finally, Armistice Capital LLC grew its position in 4D Molecular Therapeutics by 76.6% in the fourth quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock worth $14,520,000 after buying an additional 840,000 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.